Liver Tumor Enhancement at Hybrid Angio-CT and Comparison With Tumor and Hepatic Parenchymal Distribution of Yttrium-90 Microspheres by Positron Emission Tomography
- PMID: 38169929
- PMCID: PMC10759247
- DOI: 10.7759/cureus.49861
Liver Tumor Enhancement at Hybrid Angio-CT and Comparison With Tumor and Hepatic Parenchymal Distribution of Yttrium-90 Microspheres by Positron Emission Tomography
Abstract
This single-center retrospective study evaluated patients who underwent treatment of a primary or secondary hepatic malignancy with injection of glass or resin yttrium-90 (90Y) microspheres with a corresponding hybrid angiography-computed tomography (angio-CT) and 90Y positron emission tomography (PET). Volumetric contours were defined by three independent observers and were used to calculate relative tumoral enhancement at angio-CT. This parameter was compared with the tumor-to-normal (T/N) activity ratio predicted by technetium-99m macro-aggregated albumin (99mTc-MAA) single photon emission computed tomography (SPECT) and microsphere activity distribution by 90Y PET. A similar correlation was observed for the enhancement ratio at angio-CT with observed microsphere distribution at 90Y PET (r=0.34) to that predicted by 99mTc-MAA SPECT (r=0.32). The enhancement ratio on angio-CT performed as well as 99mTc-MAA in the prediction of 90Y PET activity distribution. The technique could not be readily applied to tumors with large areas of hypoattenuation (necrosis) on angio-CT. With refinement and further study, this technique could be used as a quantitative adjunct to standard-of-care 99mTc-MAA SPECT for dosimetry calculations and prediction of microsphere distribution to maximize tumor response and minimize hepatotoxicity.
Keywords: angiography; hepatocellular carcinoma; interventional radiology; liver metastases; positron emission tomography; radiation microsphere therapy; radioembolization; selective internal radiotherapy; yttrium-90.
Copyright © 2023, Campbell et al.
Conflict of interest statement
The authors have declared financial relationships, which are detailed in the next section.
Figures









Similar articles
-
PET/CT-Based Dosimetry in 90Y-Microsphere Selective Internal Radiation Therapy: Single Cohort Comparison With Pretreatment Planning on (99m)Tc-MAA Imaging and Correlation With Treatment Efficacy.Medicine (Baltimore). 2015 Jun;94(23):e945. doi: 10.1097/MD.0000000000000945. Medicine (Baltimore). 2015. PMID: 26061323 Free PMC article.
-
Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.J Vasc Interv Radiol. 2017 May;28(5):722-730.e1. doi: 10.1016/j.jvir.2016.12.1221. Epub 2017 Feb 24. J Vasc Interv Radiol. 2017. PMID: 28238581
-
99mTc-macroaggregated albumin SPECT/CT predictive dosimetry and dose-response relationship in uveal melanoma liver metastases treated with first-line selective internal radiation therapy.Sci Rep. 2023 Aug 12;13(1):13118. doi: 10.1038/s41598-023-39994-7. Sci Rep. 2023. PMID: 37573346 Free PMC article.
-
Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):559-75. doi: 10.1007/s00259-015-3157-8. Epub 2015 Sep 4. Eur J Nucl Med Mol Imaging. 2016. PMID: 26338177 Free PMC article. Review.
-
90Y-Loaded Microsphere SIRT of HCC Patients With Portal Vein Thrombosis: High Clinical Impact of 99mTc-MAA SPECT/CT-Based Dosimetry.Semin Nucl Med. 2019 May;49(3):218-226. doi: 10.1053/j.semnuclmed.2019.01.006. Epub 2019 Feb 7. Semin Nucl Med. 2019. PMID: 30954188 Review.
Cited by
-
An Evaluation of 90Y Bremsstrahlung SPECT Image Quality in the Presence of 99mTc: A Technical Perspective on Same-Day Radioembolization.Curr Oncol. 2024 Nov 26;31(12):7511-7522. doi: 10.3390/curroncol31120554. Curr Oncol. 2024. PMID: 39727677 Free PMC article.
References
-
- Radiomicrosphere dosimetry: principles and current state of the art. Gulec SA, McGoron AJ. Semin Nucl Med. 2022;52:215–228. - PubMed
-
- Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE- 01): a randomised, multicentre, open-label phase 2 trial. Garin E, Tselikas L, Guiu B, et al. Lancet Gastroenterol Hepatol. 2021;6:17–29. - PubMed
-
- Diagnostic pharmaco-scintigraphy with hepatic intra-arterial technetium-99m macroaggregated albumin in the determination of tumour to non-tumour uptake ratio in hepatocellular carcinoma. Lau WY, Leung TW, Ho S, et al. Br J Radiol. 1994;67:136–139. - PubMed
LinkOut - more resources
Full Text Sources